Osteoporosis Drugs Market by Drug Type, Route of Administration, Application

Description

List of Tables

The Global Osteoporosis Drugs Market is forecasted to grow significantly, with a projected USD 8,324.71 million in 2023 at a CAGR of 5.56% and expected to reach a staggering USD 12,192.61 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Osteoporosis Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Osteoporosis Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and Selective Estrogen Inhibitors Modulator. The Bisphosphonates commanded largest market share of 31.09% in 2022, followed by Calcitonin.

Based on Route of Administration, market is studied across Injectable and Oral. The Oral commanded largest market share of 62.86% in 2022, followed by Injectable.

Based on Application, market is studied across Primary Osteoporosis and Secondary Osteoporosis. The Primary Osteoporosis commanded largest market share of 61.34% in 2022, followed by Secondary Osteoporosis.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.56% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Osteoporosis Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Osteoporosis Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Osteoporosis Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Osteoporosis Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Osteoporosis Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Osteoporosis Drugs Market?

6. What is the market share of the leading vendors in the Global Osteoporosis Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Osteoporosis Drugs Market?

Product Code: MRR-AD36CD898103

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Osteoporosis Drugs Market, by Drug Type, 2022 vs 2030
4.3. Osteoporosis Drugs Market, by Route of Administration, 2022 vs 2030
4.4. Osteoporosis Drugs Market, by Application, 2022 vs 2030
4.5. Osteoporosis Drugs Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
  - 5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
- 5.1.2. Restraints
  - 5.1.2.1. Concerns over patent expiration of osteoporosis drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging product development and research activities in healthcare organizations
  - 5.1.3.2. Proliferation in the research funding from various organizations
- 5.1.4. Challenges
  - 5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Osteoporosis Drugs Market, by Drug Type

6.1. Introduction
6.2. Bisphosphonates
6.3. Calcitonin
6.4. Parathyroid Hormone Therapy
6.5. Rank Ligand Inhibitors
6.6. Selective Estrogen Inhibitors Modulator

7. Osteoporosis Drugs Market, by Route of Administration

7.1. Introduction
7.2. Injectable
7.3. Oral

8. Osteoporosis Drugs Market, by Application

8.1. Introduction
8.2. Primary Osteoporosis
8.3. Secondary Osteoporosis

9. Americas Osteoporosis Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Osteoporosis Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Osteoporosis Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
  - 12.3.1.2. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
- 12.3.2. Agreement, Collaboration, & Partnership
  - 12.3.2.1. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
  - 12.3.2.2. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
  - 12.3.2.3. Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan.
- 12.3.3. New Product Launch & Enhancement
  - 12.3.3.1. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
- 12.3.4. Investment & Funding
  - 12.3.4.1. New funding for osteoporosis research announced
- 12.3.5. Award, Recognition, & Expansion
  - 12.3.5.1. FDA Clears Tymlos for Osteoporosis in Men
  - 12.3.5.2. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
  - 12.3.5.3. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche

13. List of Company Mentioned

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing